JZJ(SH:605266) Xin Lang Cai Jing·2025-09-27 00:30Core Viewpoint - The company reported stable revenue with a significant improvement in profit, driven by effective cost control and a low base from the previous year [1][3]. Financial Performance - In 1H25, the company achieved revenue of 4.46 billion yuan, a slight decrease of 0.6% year-on-year, while net profit attributable to shareholders was 70 million yuan, an increase of 15.1% year-on-year [1]. - In Q2 25, revenue was 2.16 billion yuan, down 0.4% year-on-year and down 5.7% quarter-on-quarter, with net profit attributable to shareholders reaching 40 million yuan, up 265.9% year-on-year and up 15.9% quarter-on-quarter [1]. - The company’s gross profit margin for 1H25 was 35.7%, a decrease of 0.2 percentage points year-on-year, while the net profit margin was 1.6%, an increase of 0.2 percentage points year-on-year [3]. Operational Adjustments - The company adjusted its store expansion strategy, focusing on improving existing stores amid industry consolidation, resulting in a net decrease of 22 stores to a total of 5,464 stores by the end of 1H25 [2]. - The revenue from the pharmaceutical retail business in 1H25 was 4.02 billion yuan, down 0.4% year-on-year, with a gross margin of 35.0%, an increase of 0.1 percentage points year-on-year [2]. Product Performance - Prescription drug revenue was 1.47 billion yuan, down 6.7% year-on-year, while non-prescription drug revenue increased by 3.9% to 1.76 billion yuan [2]. - The revenue from traditional Chinese medicine was 150 million yuan, down 11.7% year-on-year, and medical device revenue was 330 million yuan, up 5.1% year-on-year [2]. Cash Flow and Cost Management - The net cash flow from operating activities in 1H25 was 551 million yuan, a significant improvement from 290 million yuan in 1H24 [3]. - The company implemented comprehensive cost control measures, including managing rental, labor, and distribution costs, which contributed to the improved profit margins [1][3]. Investment Outlook - The company is positioned to benefit from ongoing industry consolidation, with adjusted net profit forecasts for 2025-2027 being 170 million, 210 million, and 260 million yuan, reflecting year-on-year growth of 36%, 22%, and 22% respectively [3]. - A target price of 22.5 yuan is set based on a 20x target PE for 2025, maintaining a "recommended" rating [3].